docetaxel anhydrous and platinum
docetaxel anhydrous has been researched along with platinum in 69 studies
Compound Research Comparison
Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (platinum) | Trials (platinum) | Recent Studies (post-2010) (platinum) |
---|---|---|---|---|---|
12,110 | 3,216 | 6,920 | 11,422 | 457 | 6,106 |
Research
Studies (69)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (2.90) | 18.2507 |
2000's | 10 (14.49) | 29.6817 |
2010's | 28 (40.58) | 24.3611 |
2020's | 29 (42.03) | 2.80 |
Authors
Authors | Studies |
---|---|
Armand, JP; Cunningham, D; Kohne, CH; Misset, JL; van Cutsem, E | 1 |
Kaye, SB | 1 |
Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
Andre, F; Fandi, A; Fossella, F; Herbst, RS; Le Chevalier, T; Lee, JJ; Liu, DD; Massarelli, E; Ochs, J; Wolf, M | 1 |
Kitajima, M; Kubota, T; Kumai, K; Maeda, S; Otani, Y; Saikawa, Y; Sugiura, T | 1 |
Sugiyama, T | 1 |
Belani, CP; Fidias, P; Fossella, F; Gorbounova, V; Kaukel, E; Mattson, KV; Millward, M; Pereira, JR; Pluzanska, A; Ramlau, R; Szczesna, A; von Pawel, J | 1 |
Lester, JF; Macbeth, FR | 1 |
Boku, N; Ebihara, M; Iida, Y; Onitsuka, T; Onozawa, Y; Zenda, S | 1 |
Lee, R; Leighl, NB; Loreto, M; Ng, R | 1 |
Enomoto, T; Fukutsuji, K; Ikeda, H; Kitano, H; Morizane, R; Nakahara, K; Nosaka, A; Sakoda, T; Shibano, A; Yamanishi, M | 1 |
Lu, S; Yu, YF; Zhang, YF | 1 |
Berard, H; Bota, S; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Paillotin, D; Robinet, G; Thomas, P; Vergnenegre, A | 1 |
Fan, Y; Huang, ZY; Luo, LH; Yu, HF | 1 |
Kajiura, Y; Yagata, H; Yamauchi, H | 1 |
Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T | 1 |
Berchuck, A; Havrilesky, LJ; Higgins, RV; Kohler, MF; Myers, ER; Nycum, LR; Pokrzywinski, R; Revicki, D; Secord, AA | 1 |
Bennouna, J; de Castro, J; Dingemans, AM; Gridelli, C; Griesinger, F; Grossi, F; Langer, C; Rossi, A; Thatcher, N; Wong, EK | 1 |
Douillard, JY; Jiang, GL; Kim, ES; Li, LY; Liao, ML; Milenkova, T; Sun, Y; Wu, YL | 1 |
Alvarez Secord, A; Berchuck, A; Havrilesky, LJ; Higgins, RV; Holloway, RW; Kohler, MF; Lewandowski, GS; Nycum, LR; Puls, LE; Valea, FA | 1 |
Kamura, T; Kuzuya, K; Noda, K; Ochiai, K; Sugiyama, T; Tamura, K; Ushijima, K | 1 |
Jaśkiewicz, P; Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Winiarczyk, K; Wojas-Krawczyk, K | 1 |
Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yi, JH; Yim, DS | 1 |
Chi, Y; Cui, CX; Li, YS; Lü, N; Song, Y; Sun, YK; Wang, JW; Yang, L; Yuan, XH; Zhang, W; Zhou, AP | 1 |
Baldotto, C; Bennouna, J; Ciuleanu, TE; Goksel, T; Gorbunova, V; Le-Guennec, S; Miller, V; Novello, S; Ozguroglu, M; Ramlau, R; Rey, A; Scagliotti, G; Shepherd, FA; Thatcher, N | 1 |
Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
Cai, R; Liu, T; Lu, D; Wang, W; Wu, H; Zhuang, X | 1 |
Alexandris, E; Arrieta, O; Bidoli, P; Cappuzzo, F; Ciuleanu, TE; Czyzewicz, G; Dakhil, S; Gans, S; Garon, EB; Goksel, T; Gorbunova, V; Grigorescu, A; Karaseva, N; Kim, JH; Kowalyszyn, RD; Lewanski, CR; Orlov, SV; Park, K; Pérol, M; Pikiel, J; Prabhash, K; Reck, M; Sashegyi, A; Syrigos, KN; Thomas, M; Yurasov, S | 1 |
Georgoulias, V; Giagkas, G; Ioannidis, G; Koutsopoulos, A; Lagoudaki, E; Mavroudis, D; Papadaki, C; Sfakianaki, M; Souglakos, J; Trypaki, M; Tsakalaki, E; Voutsina, A | 1 |
Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishikawa, A; Okita, N; Sasaki, Y; Sawada, R; Shimada, Y; Shirakawa, T; Shoji, H; Takahashi, N; Takashima, A; Yamada, Y | 1 |
Hata, A; Hattori, Y; Imamura, F; Kaneda, T; Katakami, N; Kumagai, T; Morita, S; Negoro, S; Nishimura, T; Nishino, K; Okuda, C; Satouchi, M; Tachihara, M; Urata, Y; Yokota, S | 1 |
Baha, A; Ozturk, C; Yıldırım, F; Yurdakul, AS | 1 |
Arrieta, O; Cappuzzo, F; Carter, GC; Ciuleanu, TE; Dakhil, S; Garon, EB; Goksel, T; Karaseva, N; Kim, JH; Kowalyszyn, RD; Lee, P; Lewanski, CR; Park, K; Pérol, M; Pikiel, J; Prabhash, K; Reck, M; Syrigos, KN; Thomas, M; Yurasov, S; Zimmermann, A | 1 |
Enatsu, S; Ferry, D; Hosomi, Y; Kasahara, K; Koue, T; Lee, P; Nakagawa, K; Nakamura, T; Nishio, M; Ohe, Y; Takahashi, T; Tamura, T; Yamada, K; Yamamoto, N; Yoh, K | 1 |
James, ND; Ritchie, AWS; Sydes, MR | 1 |
Berghmans, T; Biesma, B; Chittazhathu Kurian Kuruvilla, Y; Ciardiello, F; Coate, L; Cobo Dols, M; Collado Martin, R; Cuffe, S; Curioni-Fontecedro, A; Dafni, U; de Hosson, S; Garde Noguera, J; Gasca-Ruchti, A; Gautschi, O; Gregorc, V; Groen, HJM; Horgan, A; Insa, A; Juan Vidal, Ó; Kassapian, M; Láng, I; López Martín, A; Mark, MT; Massutí, B; Meldgaard, P; Novello, S; Palmero Sanchez, R; Peralta, S; Peters, S; Pieterman, R; Ponce Aix, S; Rauch, D; Smit, EF; Stahel, RA; Summers, Y; Torri, V; Tsourti, Z; van den Berg, PM; van Heemst, R; van Henten, AMJ; Villa Guzmán, JC; Zielinski, CC | 1 |
Hisada, T; Imai, H; Kaira, K; Kotake, M; Minato, K; Miura, Y; Mori, K; Saito, R; Sakurai, R; Tomizawa, Y | 1 |
Goto, A; Horita, N; Ito, K; Kaneko, T; Nagashima, A; Nakashima, K; Shibata, Y; Yamanaka, T | 1 |
Karachaliou, N; Rosell, R | 1 |
Chang, SS | 1 |
Lotan, Y; Meng, X | 1 |
Alexandris, E; Brustugun, OT; Cuyun Carter, G; Gans, S; Garon, EB; Gautschi, O; Iglesias Docampo, L; Kalofonos, H; Kim, JH; Lee, P; Orlov, SV; Oton, AB; Pérol, M; Reck, M; Scagliotti, GV; Socinski, MA; Stefaniak, VJ; Thomas, M; Wolff, K; Zimmermann, AH | 1 |
Arriola, E; Cui, ZL; Garon, EB; Levy, B; Mekhail, T; Molife, C; Pérol, M; Winfree, KB | 1 |
Cai, R; Chen, S; Chen, X; Chen, Y; Fan, Y; Guan, Y; Lan, B; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Zhang, P; Zhao, W | 1 |
Aytes, A; Bakht, M; Beltran, H; Buisan, O; Bystrup, S; Castro, E; Conteduca, V; Font, A; Indacochea, A; Jimenez, N; Marin-Aguilera, M; Martinez-Balibrea, E; Mellado, B; Olmos, D; Palomero, L; Pardo, JC; Piulats, JM; Ruiz de Porras, V; Solé-Blanch, C; Suarez, JF; Wang, XC | 1 |
Bajars, M; Barlesi, F; Manitz, J; Özgüroğlu, M; Park, K; Ruisi, M; Spigel, D; Vansteenkiste, J; Yang, JC | 1 |
Hwang, M; Seiwert, TY | 1 |
Arén Frontera, O; Bajars, M; Barlesi, F; Calabrò, L; de Marinis, F; Garassino, M; Ishii, H; Krzakowski, M; Lee, JS; Özgüroğlu, M; Park, K; Polychronis, A; Ruisi, M; Spigel, D; Szczesna, A; Uslu, R; Vansteenkiste, J; Xiong, H; Yang, JCH | 1 |
Honma, Y; Ishiki, H; Kosaka, M | 1 |
Auperin, A; Bourhis, J; Fraslin, A; Guigay, J; Keilholz, U; Mesia, R | 1 |
Donix, L; Dubrovska, A; Erb, HHH; Erdmann, K; Fuessel, S; Peitzsch, C; Pfeifer, M; Thomas, C | 1 |
Bamias, A; Bell-McGuinn, KM; Castellano, D; de Wit, R; Drakaki, A; Fléchon, A; Gao, L; Lee, JL; Long, A; Matsubara, N; Necchi, A; Petrylak, DP; Powles, T; Sternberg, CN; van der Heijden, MS; Walgren, RA; Yu, EY; Zimmermann, AH | 1 |
Bellile, E; Bradford, CR; Carey, TE; Casper, K; Chinn, SB; Dragovic, AF; Eisbruch, A; Jolly, S; Kupfer, R; Malloy, KM; Mierzwa, ML; Prince, ME; Shuman, AG; Spector, ME; Srinivasan, A; Stucken, C; Swiecicki, PL; Wolf, GT; Worden, FP | 1 |
Gu, Q; Li, S | 1 |
Carlisle, J; Chen, Z; Dhodapkar, M; Leal, T; Liu, Y; Osta, BE; Owonikoko, T; Pakkala, S; Ramalingam, S; Steuer, C | 1 |
Rodriguez, E; Santos, ES | 1 |
Bessho, A; Furuya, N; Goto, Y; Harada, T; Kawashima, Y; Misumi, T; Miura, S; Nakahara, Y; Nakamura, Y; Naoki, K; Okamoto, H; Seike, M; Shimokawa, T; Shiraishi, Y; Takiguchi, Y; Tanaka, H; Taniguchi, Y; Tokito, T; Uchiyama, A | 1 |
Chang, KM; Hung, CJ; Kang, BH; Kang, YY; Lee, CC; Yin, CH | 1 |
Chen, Q; Chen, Y; Guo, J; Li, X; Lin, J; Lin, M; Lin, W; Weng, Y; Yu, X; Zeng, S; Zheng, X | 1 |
Hua, X; Liu, H; Lv, T; Song, Y; Wu, X; Xu, K; Zhan, P; Zhang, F | 1 |
Ahn, MJ; Algazi, AP; Aziz, MASA; Caguioa, PB; Chan, ATC; Cheng, A; Chong, WQ; Ho, C; Ho, GF; Hong, RL; Kho, SK; Kim, SB; Lee, VHF; Massarelli, E; Ng, QS; Ngamphaiboon, N; Ngan, RK; Saraf, S; Siu, LL; Soparattanapaisarn, N; Sriuranpong, V; Swaby, RF; Tiambeng, MLA; Yen, CJ; Yuan, J; Yun, T | 1 |
Aggarwal, H; Muehlenbein, CE; Ndirangu, K; Thom, H; Tongbram, V; Winfree, KB; Zhu, E | 1 |
Colevas, AD; Coty, J; Hara, W; Jun, M; Le, QT; Lira, R; Lu, R; McMillan, A; Pinto, H; Quon, A; Winters, E | 1 |
Balbach, ML; Bestvina, C; Camidge, DR; Hsu, R; Iams, WT; Kim, C; Leal, T; Marmarelis, ME; Mehta, K; Nieva, J; Patil, T; Phillips, S; Robinson, MA; Sacher, A; Sackstein, PE; Sethakorn, N; Velcheti, V; Wang, X | 1 |
Arai, D; Ito, K; Kaira, K; Kajiwara, T; Kobayashi, K; Kodama, H; Miura, K; Miyanaga, A; Mizutani, H; Mori, K; Nakamura, A; Ninomiya, T; Oba, T; Tamiya, M; Yamaguchi, O; Yanagitani, N | 1 |
Baranwal, M; Sharma, S; Singh, N; Singh, S | 1 |
Hayashi, H; Kasahara-Kiritani, M; Nishio, M; Takahashi, M; Tsuchiya, H | 1 |
Abraham, DT; Backianathan, S; Balakrishnan, R; Chacko, RT; Cherian, AJ; George, TK; Georgy, JT; Joel, A; John, AO; Manipadam, MT; Patole, S; Paul, MJ; Ramnath, N; Rebekah, G; Sebastian, P; Sharma, P; Sigamani, E; Singh, A; Thumaty, DB | 1 |
Ahn, MJ; Burtness, B; Cohen, EEW; Dinis, J; Ge, J; Harrington, KJ; Lerman, N; Licitra, L; Lin, J; Mach, N; Machiels, JP; Mehra, R; Soria, A; Soulières, D; Swaby, RF; Tourneau, CL | 1 |
Reviews
8 review(s) available for docetaxel anhydrous and platinum
Article | Year |
---|---|
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Platinum; Quinazolines; Taxoids; Thiophenes; Topoisomerase I Inhibitors | 1999 |
Progress in the treatment of ovarian cancer. Scottish Gynaecological Cancer Trials Group.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Taxoids | 1999 |
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Platinum; Receptors, Estrogen; Taxoids | 2011 |
[A meta-analysis of platinum plus docetaxel or vinorelbine in the first-line treatment of advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2014 |
The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Platinum | 2017 |
Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung; Lung Neoplasms; Platinum | 2022 |
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immunotherapy; Lung Neoplasms; Network Meta-Analysis; Pemetrexed; Platinum | 2023 |
Trials
27 trial(s) available for docetaxel anhydrous and platinum
Article | Year |
---|---|
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pain; Patient Compliance; Platinum; Prospective Studies; Psychomotor Performance; Quality of Life; Sickness Impact Profile; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
[Docetaxel (TXT) and irinotecan (CPT-11) as a second-line chemotherapy for platinum-pretreated squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Platinum; Taxoids | 2008 |
Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prospective Studies; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2011 |
[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2010 |
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Quality of Life; Recurrence; Taxoids | 2012 |
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2011 |
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Quality of Life; Recurrence; Taxoids | 2012 |
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Topics: Adult; Aged; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Taxoids | 2013 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Platinum; Pyrroles; Salvage Therapy; Stomach Neoplasms; Sunitinib; Survival Rate; Taxoids; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
[Phase II clinical trial of docetaxel, platinum and S-1 for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Platinum; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2012 |
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Platinum; Prognosis; Proportional Hazards Models; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Platinum; Quality of Life; Ramucirumab; Survival Rate; Taxoids | 2014 |
A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Platinum; Retreatment; Taxoids; Tegafur; Treatment Outcome | 2015 |
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Platinum; Proportional Hazards Models; Quality of Life; Ramucirumab; Retreatment; Taxoids; Treatment Outcome | 2016 |
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Ramucirumab; Retreatment; Risk Factors; Taxoids; Treatment Outcome | 2016 |
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic On
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Prognosis; Survival Rate; Taxoids | 2017 |
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Neoplasm Staging; Platinum; Ramucirumab | 2020 |
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2020 |
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
Topics: Antibodies, Monoclonal, Humanized; Asia; Docetaxel; Europe; Humans; Immune Checkpoint Inhibitors; Lung; Lung Neoplasms; Platinum | 2021 |
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
Topics: Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Docetaxel; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum | 2021 |
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Humans; Platinum; Ramucirumab; Urinary Bladder Neoplasms | 2022 |
Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Humans; Induction Chemotherapy; Laryngeal Neoplasms; Organ Preservation; Platinum; Proto-Oncogene Proteins c-bcl-2 | 2022 |
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Programmed Cell Death 1 Receptor; Ramucirumab | 2022 |
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Platinum | 2022 |
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Nasopharyngeal Neoplasms; Platinum | 2023 |
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Other Studies
34 other study(ies) available for docetaxel anhydrous and platinum
Article | Year |
---|---|
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cisplatin; Docetaxel; Drug Interactions; Humans; Platinum; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured; Up-Regulation | 2004 |
Quality of life assessment in the TAX 326 study.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pain; Patient Compliance; Platinum; Psychomotor Performance; Quality of Life; Sickness Impact Profile; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Tolerance; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Taxoids; Treatment Outcome | 2007 |
Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Protein-Tyrosine Kinases; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
[Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
[Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Platinum; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2011 |
The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Predictive Value of Tests; Proportional Hazards Models; Quinazolines; Smoking; Taxoids; Tubulin | 2012 |
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan | 2013 |
PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carrier Proteins; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2014 |
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Platinum; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Hospitals, University; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids; Turkey | 2015 |
Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh's Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. Eur Urol 2016;70:707-708.
Topics: Attitude; Docetaxel; Humans; Male; Platinum; Prostatic Neoplasms; Taxoids | 2017 |
Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Proportional Hazards Models; Taxoids | 2017 |
Avelumab in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Platinum | 2018 |
Re: Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Metastatic Urothelial Carcinoma after Platinum-Based Therapy (RANGE): A Randomised, Double-Blind, Phase 3 Trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Docetaxel; Double-Blind Method; Humans; Platinum; Ramucirumab | 2019 |
Critical treatment choices for patients with platinum-refractory urothelial carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Docetaxel; Double-Blind Method; Humans; Platinum; Ramucirumab; Urologic Neoplasms | 2020 |
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Acceptance of Health Care; Platinum; Ramucirumab; Taxoids | 2021 |
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Docetaxel; Humans; Male; Mice; Platinum; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-bcl-2; Taxoids | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Platinum; Taxoids | 2021 |
Unresolved questions regarding the promise of the TPEx regimen.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Humans; Platinum | 2021 |
Unresolved questions regarding the promise of the TPEx regimen - Authors' reply.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Humans; Platinum | 2021 |
Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines.
Topics: Cell Line; Cisplatin; Docetaxel; Humans; Male; Platinum; Prostatic Neoplasms, Castration-Resistant | 2022 |
Computed Tomography Image under Artificial Intelligence Algorithm to Evaluate the Nursing and Treatment Effect of Pemetrexed Combined Platinum-Based Chemotherapy on Elderly Lung Cancer.
Topics: Aged; Antigens, Neoplasm; Artificial Intelligence; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Keratin-19; Lung Neoplasms; Pemetrexed; Platinum; Tomography; Tomography, X-Ray Computed | 2022 |
Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy.
Topics: Alanine Transaminase; Body Composition; Docetaxel; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Platinum; Retrospective Studies | 2022 |
Optimal exposure to docetaxel in adjuvant chemotherapy for early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Hemoglobins; Humans; Neutropenia; Platinum; Taxoids | 2022 |
Zebrafish patient-derived xenografts accurately and quickly reproduce treatment outcomes in non-small cell lung cancer patients.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Heterografts; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Treatment Outcome; Zebrafish | 2023 |
In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Platinum | 2023 |
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; NF-E2-Related Factor 2; Platinum; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Taxoids | 2023 |
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Platinum; Ramucirumab; Retrospective Studies; Taxoids | 2023 |
Association of
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Genotype; Humans; Lung Neoplasms; MutL Protein Homolog 1; Platinum; Polymorphism, Single Nucleotide | 2023 |
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Platinum; Protein Kinase Inhibitors; Treatment Outcome | 2023 |
Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Neoadjuvant Therapy; Platinum; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |